COMP <GO>
ANTX vs PEPG // FREE CASH FLOW YIELD
AN2 Therapeutics Inc. (NASDAQ) VS. PepGen Inc. (NASDAQ) • 15-METRIC TALLY: ANTX 2
— PEPG 0
■ METRIC PARITY
LAST: $4.35 (-3.97%) • MKT CAP: $170.9M
fcf-yield
-16.86%
LAST: $2.35 (-0.42%) • MKT CAP: $163.5M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANTX VS. PEPG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANTX | PEPG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -16.86% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.0 | 42.0 | +12.00 | ANTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.9M | $163.5M | $7.5M | ANTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANTX REV | PEPG REV | ANTX GROSS % | PEPG GROSS % | ANTX FCF | PEPG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $106.7M | $262.1M | — | — | -$29.8M | -$81.9M |
| FY 2024 | $159.0M | $273.7M | — | — | -$49.3M | -$82.9M |
| FY 2023 | $195.0M | $237.3M | — | — | -$53.3M | -$69.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANTX // BETA —
PEPG // BETA —